The report on “Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product with Price and Volume Outlook, including Executive and Consultant Guides, and Customized Forecasting and Analysis for 2023-2027”…
Castle Biosciences, Inc. (Nasdaq: CSTL), a company focused on improving patient care through innovative tests, has announced the presentation of new data showcasing the performance of its DecisionDx-Melanoma test in…
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. have made a joint announcement regarding the recent developments related to bempedoic acid (marketed as NILEMDO®) and the bempedoic acid/ezetimibe fixed combination…
Esperion (NASDAQ: ESPR) announced today that the FDA has approved expanded labels for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets. This approval is based on positive…
Bristol Myers Squibb (NYSE: BMY) has announced that the European Commission (EC) has granted approval to Abecma® (idecabtagene vicleucel; ide-cel) for treating adult patients with relapsed and refractory multiple myeloma…
Merz Aesthetics, the global leader in medical aesthetics, will showcase fresh data on its product lineup and share insights into trends in medical aesthetics at the 2024 Aesthetic and Anti-Aging…
Takeda (TSE:4502/NYSE:TAK) announced today that the FDA has approved ICLUSIG® (ponatinib) through sNDA for treating adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.…
LGM Pharma, a prominent provider of customized API and CDMO services throughout the drug product lifecycle, has unveiled major upgrades to its capabilities. This includes a 50% expansion and a…
AstraZeneca has initiated a Phase III trial to study the effects of the triple-combination inhaled therapy BREZTRI AEROSPHERE® (budesonide/glycopyrronium/formoterol fumarate, or BGF) on severe cardiopulmonary outcomes in people with chronic…
LEO Pharma, a parent company of Timber Pharmaceuticals, Inc., presents initial findings from the ASCEND trial in a late-breaking session at the 2024 American Academy of Dermatology (AAD) Annual Meeting.…
Incyte (Nasdaq:INCY) disclosed findings from a Phase 2 trial examining povorcitinib (INCB54707), an oral JAK1 inhibitor’s effectiveness and safety among adult patients with prurigo nodularis (PN). These results were presented…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has announced positive results from the Phase 2 KARDIA-2 trial of zilebesiran, an RNAi therapeutic designed to treat hypertension by…